Homegrown pharma major Lupin Ltd on Thursday said it has launched its generic version of Vimovo tablets, used for relief from arthritis, in the US market.
The product is a combination of naproxen, a non-steroidal anti-inflammatory drug, and esomeprazole magnesium coming in strengths of 375 mg/20mg and 500 mg/20 mg. It is the authorised generic for Horizon Therapeutics PLC's Vimovo delayed release tablets, Lupin said in a regulatory filing.
It is indicated in adult and adolescent patients of 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers, it added.
Citing IQVIA MAT January 2020 data, Lupin said naproxen and esomeprazole magnesium delayed-release tablets had an annual sales of approximately USD 400 million in the US.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app